82 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27597413	58	Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings.	Southern Medical University
27301679	21	Design and synthesis of potent and selective pyridazin-4(1H)-one-based PDE10A inhibitors interacting with Tyr683 in the PDE10A selectivity pocket.	Takeda Pharmaceutical
26978121	20	Discovery and modelling studies of natural ingredients from Gaultheria yunnanensis (FRANCH.) against phosphodiesterase-4.	Sun Yat-Sen University
26976215	5	Development of thieno- and benzopyrimidinone inhibitors of the Hedgehog signaling pathway reveals PDE4-dependent and PDE4-independent mechanisms of action.	Vanderbilt University School Of Medicine
26935942	41	Synthesis and evaluation of analogs of the phenylpyridazinone NPD-001 as potent trypanosomal TbrPDEB1 phosphodiesterase inhibitors and in vitro trypanocidals.	Mercachem
26681511	33	Preparation and optimization of pyrazolo[1,5-a]pyrimidines as new potent PDE4 inhibitors.	Sanofi Research Center
26526739	35	Catecholic amides as potential selective phosphodiesterase 4D inhibitors: Design, synthesis, pharmacological evaluation and structure-activity relationships.	Southern Medical University
26288683	43	Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms.	Bristol-Myers Squibb R & D
26288344	15	Discovery and Optimization of 4-(8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl)transcyclohexanecarboxylic Acid, an Improved PDE4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease (COPD).	Novartis Institutes For Biomedical Research
25936260	8	Synthesis, biological activities and pharmacokinetic properties of new fluorinated derivatives of selective PDE4D inhibitors.	University Of Genoa
26005524	147	Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes.	Merck Research Laboratories
25815146	29	Pyrido[4,3-e][1,2,4]triazolo[4,3-a]pyrazines as Selective, Brain Penetrant Phosphodiesterase 2 (PDE2) Inhibitors.	Janssen Pharmaceutica
25736998	37	Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors.	Merck Serono
25126889	10	Synthesis, biological evaluation, and molecular modeling of new 3-(cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) Oxime (GEBR-7b) related phosphodiesterase 4D (PDE4D) inhibitors.	University Of Genoa
24998378	62	Discovery of triazines as selective PDE4B versus PDE4D inhibitors.	Northern Illinois University
24984230	22	Discovery and early clinical development of 2-{6-[2-(3,5-dichloro-4-pyridyl)acetyl]-2,3-dimethoxyphenoxy}-N-propylacetamide (LEO 29102), a soft-drug inhibitor of phosphodiesterase 4 for topical treatment of atopic dermatitis.	Leo Pharma
25075977	12	Prostaglandin Derivatives: Nonaromatic Phosphodiesterase-4 Inhibitors from the Soft Coral Sarcophyton ehrenbergi.	Sun Yat-Sen University
25456383	113	Synthesis and preliminary biological evaluation of potent and selective 2-(3-alkoxy-1-azetidinyl) quinolines as novel PDE10A inhibitors with improved solubility.	TBA
25264825	54	Modulation of cAMP-specific PDE without emetogenic activity: new sulfide-like PDE7 inhibitors.	Centro De Investigaciones Biol�Gicas (Csic)
25221665	33	Structure-Based Design of a Potent, Selective, and Brain Penetrating PDE2 Inhibitor with Demonstrated Target Engagement.	Janssen Pharmaceutica
25149511	34	Novel Roflumilast analogs as soft PDE4 inhibitors.	Amakem
24785301	83	Efficacious inhaled PDE4 inhibitors with low emetic potential and long duration of action for the treatment of COPD.	Astrazeneca
24597921	14	Prenylated coumarins: natural phosphodiesterase-4 inhibitors from Toddalia asiatica.	Sun Yat-Sen University
9873708	16	N-arylrolipram derivatives as potent and selective PDE4 inhibitors.	Novartis Horsham Research Center
23294698	8	Discovery of novel 1,4-dihydropyridine-based PDE4 inhibitors.	University Of Hyderabad Campus
23149228	60	Discovery of selective biaryl ethers as PDE10A inhibitors: improvement in potency and mitigation of Pgp-mediated efflux.	Amgen
22985069	18	Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design.	Sun Yat-Sen University
22963052	38	Catechol pyrazolinones as trypanocidals: fragment-based design, synthesis, and pharmacological evaluation of nanomolar inhibitors of trypanosomal phosphodiesterase B1.	Vu University Amsterdam
22944118	27	Imidazopyridazinones as novel PDE7 inhibitors: SAR and in vivo studies in Parkinson's disease model.	Glenmark Pharmaceuticals
22891752	18	Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors.	Universidade Federal Do Rio De Janeiro
22889281	36	Solubility-driven optimization of phosphodiesterase-4 inhibitors leading to a clinical candidate.	Novartis Institutes For Biomedical Research
22385507	20	Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds.	Instituto De Qu£Mica M£Dica (Csic)
22483586	10	Moracin M from Morus alba L. is a natural phosphodiesterase-4 inhibitor.	Sun Yat-Sen University
22401864	61	Discovery of oxazole-based PDE4 inhibitors with picomolar potency.	Merck Research Laboratories
20188577	23	In silico search for multi-target anti-inflammatories in Chinese herbs and formulas.	King'S College London
19014888	52	Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression.	Human Biomolecular Research Institute
18686943	28	Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.	Matrix Laboratories
17337182	23	Potent and selective xanthine-based inhibitors of phosphodiesterase 5.	Novartis Institutes Of Biomedical Research
17228876	36	SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.	Pfizer
16168647	80	Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.	Merck Frosst Centre For Therapeutic Research
15887951	29	The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.	Monash University (Parkville Campus)
11405657	123	Novel, potent, and selective phosphodiesterase 5 inhibitors: synthesis and biological activities of a series of 4-aryl-1-isoquinolinone derivatives.	Tanabe Seiyaku
10691693	64	Palladium-catalyzed cross-coupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: a novel class of potent and selective phosphodiesterase type 4D inhibitors.	Novartis Pharma
10090791	77	Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives.	Tanabe Seiyaku
11755362	24	Synthesis of 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridine-6-yl)-benzoic acid: a potent and selective phosphodiesterase type 4D inhibitor.	Novartis Pharma
22030030	5	Thiophene inhibitors of PDE4: crystal structures show a second binding mode at the catalytic domain of PDE4D2.	Monash University (Parkville Campus)
21871695	46	Synthesis and biological activity of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel and potent phosphodiesterase type 4 inhibitors.	RhôNe-Poulenc Rorer
20933411	69	Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.	Merck Frosst Centre For Therapeutic Research
19447034	76	Discovery of selective PDE4B inhibitors.	Asahi Kasei Pharma
21602043	50	Triazoloquinazolines as a novel class of phosphodiesterase 10A (PDE10A) inhibitors.	H. Lundbeck
21087867	30	Synthesis and SAR study of new phenylimidazole-pyrazolo[1,5-c]quinazolines as potent phosphodiesterase 10A inhibitors.	Universit£
20825218	69	Synthesis and biological activity of pyrido[3',2':4,5]thieno[3,2-d]pyrimidines as phosphodiesterase type 4 inhibitors.	RhôNe-Poulenc Rorer
20813948	63	Spiroindolones, a potent compound class for the treatment of malaria.	Swiss Tropical And Public Health Institute
20709547	69	The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors.	Merck Frosst Centre For Therapeutic Research
20202838	62	Identification of pyridazino[4,5-b]indolizines as selective PDE4B inhibitors.	Pfizer
19361990	7	Surface plasmon resonance-based detection of ladder-shaped polyethers by inhibition detection method.	Osaka University
20053559	55	Design, synthesis, and evaluation of 2-aryl-7-(3',4'-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidines as novel PDE-4 inhibitors.	Korea Research Institute Of Chemical Technology
20196613	32	Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5).	Pfizer
19744860	19	Synthesis and biological evaluation of novel phthalazinone derivatives as topically active phosphodiesterase 4 inhibitors.	Kyoto 601-8550
19631533	126	Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one.	Pfizer
19827751	21	New selective phosphodiesterase 4D inhibitors differently acting on long, short, and supershort isoforms.	University Of Genoa
19339180	69	The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents.	Pfizer
19049349	107	Design, synthesis, and structure-activity relationship, molecular modeling, and NMR studies of a series of phenyl alkyl ketones as highly potent and selective phosphodiesterase-4 inhibitors.	Georgia State University
18945617	50	Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: design, synthesis, and evaluation as topically applied, dermal anti-scarring agents.	Pfizer
16516471	114	Nitrogen-bridged substituted 8-arylquinolines as potent PDE IV inhibitors.	Merck Frosst Center For Therapeutic Research
16275071	26	A new chemical tool for exploring the physiological function of the PDE2 isozyme.	Pfizer
16263279	37	A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.	Pfizer
15324877	90	Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2: Optimization of 5,8-disubstituted derivatives.	Pfizer
15324876	94	Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1.	Pfizer
15324874	169	Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.	Pfizer
14521415	44	The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogues.	Glaxosmithkline
10197972	133	1-Arylnaphthalene lignan: a novel scaffold for type 5 phosphodiesterase inhibitor.	Tanabe Seiyaku
9873643	75	Quinazolines: combined type 3 and 4 phosphodiesterase inhibitors.	Novartis Pharma
9464356	24	Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.	Pfizer
10087018	11	Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of mu-selective agonist and antagonist activity.	University Of Rochester
9349523	22	Cloning and expression of a human serotonin 5-HT4 receptor cDNA.	Janssen Research Foundation
7684450	26	Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]piperazine monomethanesulfonate (U-90152S), a	Upjohn